Shanghai Kehua Bio-Engineering (SHE:002022) said its unit, Xi'an Tianlong Technology, received a medical device registration certificate from China's National Medical Products Administration, according to a Thursday filing with the Shenzhen Stock Exchange.
The newly approved product, the Human CYP2D6 Genetic Polymorphism Detection Kit (Fluorescent PCR Method), is valid from Dec. 17, 2024, till Dec. 16, 2029. The kit detects specific genetic mutations in human DNA, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.